NIAID Selects New Director of the Vaccine Research Center
John R. Mascola, MD, an internationally recognised expert on HIV vaccine development, has been named the new director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In this role, he will lead a comprehensive research program aimed at the design, development and testing of candidate vaccines against HIV/AIDS, influenza and other globally important infectious diseases. He will also serve as chief of the VRC virology laboratory.
“John Mascola is a visionary leader who brings a wealth of talents as a basic scientist, clinician, clinical trialist and administrator to the helm of the Vaccine Research Center,” said NIAID Director Anthony S. Fauci, MD. “In particular, his exemplary work on elucidating the protective role of antibodies against HIV has greatly influenced current vaccine design efforts. I am confident that Dr Mascola will continue and even accelerate our momentum toward the development of novel, effective vaccines against infectious diseases.”
Dr Mascola previously served as acting director and deputy director of the VRC. He also led the center’s core virology laboratory. Among his many accomplishments, he and his colleagues were the first to demonstrate that the infusion of neutralizing antibodies could protect against mucosal HIV exposure in monkeys. Dr Mascola and his colleagues also have made advances in the study of human antibody responses to natural HIV infection, including the isolation in 2010 of two antibodies from the blood of an HIV-infected person that can neutralize more than 90% of known HIV strains. VRC researchers continue to study these and other potent neutralizing antibodies in hopes of developing an effective HIV vaccine.
“John is an innovative scientist and a great choice to lead the Vaccine Research Center,” said NIH Director Francis S. Collins, M., PhD. “His expertise in vaccine development will undoubtedly help advance important research programmes against infectious diseases such as HIV/AIDS and influenza.”
Dr Mascola graduated magna cum laude from Tufts University, Boston, and earned his medical degree from the Georgetown University School of Medicine, Washington DC. He completed a residency in internal medicine at the San Diego Naval Medical Center and a fellowship in infectious diseases at the National Naval Medical Center, Bethesda, Md., followed by a fellowship in retroviral diseases at the Walter Reed Army Institute of Research, Silver Spring, Md. Dr Mascola is a fellow of the American College of Physicians and a member of the Infectious Diseases Society of America. He has been elected to the American Society of Clinical Investigation and the Association of American Physicians.
“The Vaccine Research Center is a unique, state-of-the-art facility, with a complement of extraordinarily dedicated and talented scientists and staff. I am honored to be selected as its new director,” said Dr Mascola. “I look forward to expanding our basic research on immune responses to HIV and other infections and applying this knowledge to the development of strategies to prevent and treat human diseases.”
Dr Mascola replaces Gary J. Nabel, MD, PhD, who in November 2012 left the position of VRC Director to become the deputy to the president for Global Research and Development, senior vice president and chief scientific officer at the pharmaceutical company Sanofi.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance